Celgene Expands Use of Medidata’s Technology
Celgene has expanded its eight-year technology relationship with Medidata to add the Medidata Clinical Cloud® as its enterprise technology platform.
Medidata announced that Celgene has expanded its eight-year technology relationship with Medidata to add the Medidata Clinical Cloud® as its enterprise technology platform for all clinical trials worldwide. A Medidata Rave customer since 2008, Celgene will now include Medidata Designer® (study and protocol design); Medidata Grants Manager® (site budgeting and planning); Safety Gateway (safety reporting); Medidata CTMS® (clinical trial management); Medidata SQM® (site quality management) and Medidata Patient Cloud ePRO (electronic patient-reported outcomes). Celgene is also leveraging one of Medidata’s clinical analytics offerings, Medidata Insights, which provides advanced metrics, visualizations and industry data and benchmarks.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
